Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EBITDA (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of EBITDA data on record, last reported at -$9.0 million in Q3 2025.

  • For Q3 2025, EBITDA rose 4.95% year-over-year to -$9.0 million; the TTM value through Sep 2025 reached -$38.5 million, up 5.42%, while the annual FY2024 figure was -$40.3 million, 33.38% up from the prior year.
  • EBITDA reached -$9.0 million in Q3 2025 per ASMB's latest filing, up from -$10.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.9 million in Q1 2025 and bottomed at -$60.4 million in Q4 2021.
  • Average EBITDA over 5 years is -$18.5 million, with a median of -$16.7 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 421.13% in 2021, then soared 63.24% in 2022.
  • A 5-year view of EBITDA shows it stood at -$60.4 million in 2021, then soared by 63.24% to -$22.2 million in 2022, then skyrocketed by 51.49% to -$10.8 million in 2023, then increased by 3.51% to -$10.4 million in 2024, then grew by 13.31% to -$9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$9.0 million in Q3 2025, -$10.2 million in Q2 2025, and -$8.9 million in Q1 2025.